| __timestamp | BioCryst Pharmaceuticals, Inc. | Gilead Sciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 7461000 | 2983000000 |
| Thursday, January 1, 2015 | 13047000 | 3426000000 |
| Friday, January 1, 2016 | 11253000 | 3398000000 |
| Sunday, January 1, 2017 | 13933000 | 3878000000 |
| Monday, January 1, 2018 | 29514000 | 4056000000 |
| Tuesday, January 1, 2019 | 37121000 | 4381000000 |
| Wednesday, January 1, 2020 | 67929000 | 5151000000 |
| Friday, January 1, 2021 | 118818000 | 5246000000 |
| Saturday, January 1, 2022 | 159371000 | 5673000000 |
| Sunday, January 1, 2023 | 213894000 | 6090000000 |
| Monday, January 1, 2024 | 6091000000 |
Cracking the code
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability and growth. From 2014 to 2023, Gilead Sciences, Inc. and BioCryst Pharmaceuticals, Inc. have shown contrasting trends in their SG&A expenditures. Gilead Sciences, a giant in the biotech industry, consistently spent significantly more on SG&A, peaking at approximately $6.1 billion in 2023. This represents a steady increase of around 104% over the decade. In contrast, BioCryst Pharmaceuticals, a smaller player, saw its SG&A expenses grow from about $7.5 million in 2014 to $214 million in 2023, marking an exponential increase of nearly 2,770%. This stark difference highlights the varying scales and strategies of these companies in managing operational costs. As the biotech landscape evolves, understanding these financial dynamics becomes essential for investors and industry analysts alike.
Operational Costs Compared: SG&A Analysis of Novo Nordisk A/S and BioCryst Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Merck & Co., Inc. and BioCryst Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Gilead Sciences, Inc. vs Biogen Inc.
Cost Management Insights: SG&A Expenses for Gilead Sciences, Inc. and Genmab A/S
SG&A Efficiency Analysis: Comparing Gilead Sciences, Inc. and Ascendis Pharma A/S
Gilead Sciences, Inc. or Merus N.V.: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Gilead Sciences, Inc. and MorphoSys AG
Operational Costs Compared: SG&A Analysis of Gilead Sciences, Inc. and Veracyte, Inc.
Operational Costs Compared: SG&A Analysis of Gilead Sciences, Inc. and Iovance Biotherapeutics, Inc.
Comparing SG&A Expenses: Sarepta Therapeutics, Inc. vs BioCryst Pharmaceuticals, Inc. Trends and Insights
Selling, General, and Administrative Costs: Amneal Pharmaceuticals, Inc. vs BioCryst Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Xenon Pharmaceuticals Inc. vs BioCryst Pharmaceuticals, Inc.